Dr. Aly Abayazeed, Co-Founder and Chief Medical Officer, presented findings from Neosoma's high-grade glioma tumor segmentation architecture under the abstract, "Clinical Translation: Development And Performance Testing Of A Generalizable And Reproducible High-Grade Glioma MRI Segmentation And Volumetric Analysis Deep-Learning Network For Longitudinal Assessment To Clinically Inform The Modified Response Assessment In Neuro-Oncology Criteria"
This abstract (below) and presentation (available through a download link) highlighted Neosoma's high-level NS-HGlio algorithm architectural design and empirical validation results.
Neosoma - CLINICAI_Clinical Translation Development and Performance Testing NS-HGlio
.pdf
Download PDF • 1.58MB